- Home
- CPRX vs MRUS Comparison
CPRX vs MRUS Comparison
Compare CPRX & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- MRUS
- Stock Information
- Founded
- CPRX 2002
- MRUS 2003
- Country
- CPRX United States
- MRUS Netherlands
- Employees
- CPRX N/A
- MRUS N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- MRUS Health Care
- Exchange
- CPRX Nasdaq
- MRUS Nasdaq
- Market Cap
- CPRX 2.8B
- MRUS 2.7B
- IPO Year
- CPRX 2006
- MRUS 2016
- Fundamental
- Price
- CPRX $22.52
- MRUS $43.06
- Analyst Decision
- CPRX Strong Buy
- MRUS Strong Buy
- Analyst Count
- CPRX 7
- MRUS 13
- Target Price
- CPRX $32.29
- MRUS $86.85
- AVG Volume (30 Days)
- CPRX 1.7M
- MRUS 872.0K
- Earning Date
- CPRX 05-07-2025
- MRUS 05-07-2025
- Dividend Yield
- CPRX N/A
- MRUS N/A
- EPS Growth
- CPRX 107.94
- MRUS N/A
- EPS
- CPRX 1.31
- MRUS N/A
- Revenue
- CPRX $491,734,000.00
- MRUS $36,133,000.00
- Revenue This Year
- CPRX $15.17
- MRUS $26.81
- Revenue Next Year
- CPRX $9.61
- MRUS $23.85
- P/E Ratio
- CPRX $17.19
- MRUS N/A
- Revenue Growth
- CPRX 23.49
- MRUS N/A
- 52 Week Low
- CPRX $14.47
- MRUS $33.19
- 52 Week High
- CPRX $26.16
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- CPRX 48.15
- MRUS 51.15
- Support Level
- CPRX $21.93
- MRUS $33.19
- Resistance Level
- CPRX $23.27
- MRUS $43.46
- Average True Range (ATR)
- CPRX 1.27
- MRUS 3.53
- MACD
- CPRX -0.14
- MRUS 0.34
- Stochastic Oscillator
- CPRX 50.60
- MRUS 80.53
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.